Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/4d1b09e9-8114-4477-b472-fc0b09a640f2/

MLYS

Mineralys Therapeutics, Inc. Common Stock
Chart
27.09 USD
Latest Week 2026-07-17
HealthcareBiotechnologyMID
Snapshot 2026-07-19 · 0.6w · Fresh
0.49
OS Score
48.0%
Value
47.0%
Quality
48.0%
Momentum
3/9
F-Score
0.475
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
1 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
Yes
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
48.0%ile
P/B
3.7×
FCF Yield
-0.060
SH Yield
-0.171
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
52.00000000
/100 — 1=cheapest
VC2 (Trending Value)
53.00000000
/100
VC3 (Buyback)
53.00000000
/100
Negative FCF yield (-6.0%) — the business is currently cash-consumptive.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
47.0%ile
ROE
-0.238
ROA
-0.232
GPA
0.000
D/E
0.02
Current
44.33
F-Score
3/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Stability
0.174
lower=better
Accruals
-0.024
lower=better
5yr Consist
Yes
Conservative balance sheet with D/E of 0.02.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
48.0%ile
6M Return
-17.3%
12M Return
90.4%
12-1 Mom
73.1%
Risk-Adj
0.54
Vol 252d
136.3%
Vol 60d
118.0%
↓ Contracting
Max DD 12M
-45.8%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of 73% is very strong — a clear uptrend.
OS
Composite & Factor Heatmap
All factors at a glance
0.49
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 500 peers
Sector Value %ile
23.4%
Sector Quality %ile
21.4%
P/B z-score
-0.14
Sector Avg OS
64.1%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
FBIOP Fortress Biotech Inc Pref Series A 99.0% 98.0% 84.0% 96.0%
IRWD Ironwood Pharmaceuticals Inc 99.0% 92.0% 91.0% 98.0%
CGEN Compugen 98.0% 89.0% 96.0% 82.0%
RIGL Rigel Pharmaceuticals Inc 98.0% 90.0% 93.0% 93.0%
FBIO Fortress Biotech Inc 98.0% 98.0% 84.0% 88.0%
NUTX Nutex Health Inc 98.0% 91.0% 98.0% 80.0%
TBPH Theravance Biopharma Inc 98.0% 90.0% 99.0% 84.0%
MD Mednax Inc 97.0% 85.0% 84.0% 93.0%
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
F
18.9% avg (3 factors)
Quality
D
44.8% avg (6 factors)
Momentum
B
63.6% avg (4 factors)
Risk
F
0.0% avg (1 factors)
Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends7 snapshots
Factor Persistence7 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.490—0—
Value %ile0.480—0—
Quality %ile0.470—0—
Momentum %ile0.480—0—
F-Score3.000—7—
Confidence0.616—0—
Volatility1.363—7—
Value Lens2021-07-20 → 2026-07-19
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
Price / Book
3.74
FCF Yield
-6.0%
Shareholder Yield
Div + net buyback / mktcap
-17.1%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
-23.8%
Return on Assets
-23.2%
Gross Profit / Assets
Novy-Marx GPA
-0.0%
Debt / Equity
0.02
Current Ratio
44.33
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.024
MomentumPrice trend strength over different horizons
6M Return
-17.3%
12M Return
90.4%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
73.1%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
0.54
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Earnings Stability (CV)
Lower = more stable
0.174
5yr Consistent
EPS up every year for 5 years
Yes
Piotroski F-Score
3
Buyback Yield
-17.1%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
52
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
53
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
53
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity